NEFA (drug)
NEFA is a moderate affinity NMDA antagonist (IC50 = 0.51 μM). It is a structural analog of phencyclidine.[1] It was first synthesized by a team at Parke-Davis in the late 1950s.[2]
![]() | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C15H19N |
| Molar mass | 213.324 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
References
- Dilmore JG, Johnson JW (1998). "Open channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine". Biophysical Journal. 75 (4): 1801–16. Bibcode:1998BpJ....75.1801D. doi:10.1016/S0006-3495(98)77622-2. PMC 1299852. PMID 9746522.
- GB Patent 893920 - Polycyclic amino compounds and methods for their production
| AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
|---|---|
| KARTooltip Kainate receptor |
|
| NMDARTooltip N-Methyl-D-aspartate receptor |
|
| |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
